EF Hutton Acquisition Co. I Upgrades Marinus Pharmaceuticals (NASDAQ:MRNS) to Strong-Buy

Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by equities researchers at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued on Monday, Zacks.com reports.

Other analysts have also issued reports about the company. Truist Financial reissued a “buy” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, September 26th. JMP Securities restated a “market outperform” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Monday, September 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Price Performance

NASDAQ:MRNS opened at $1.67 on Monday. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $2.42. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26. The firm has a market cap of $91.74 million, a price-to-earnings ratio of -0.63 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million during the quarter, compared to analyst estimates of $9.05 million. During the same quarter last year, the company posted ($0.61) EPS. Equities research analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its holdings in Marinus Pharmaceuticals by 31.4% in the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after purchasing an additional 990,607 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth $813,000. Renaissance Technologies LLC acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $727,000. Superstring Capital Management LP purchased a new stake in shares of Marinus Pharmaceuticals in the 4th quarter valued at $5,027,000. Finally, XTX Topco Ltd acquired a new position in Marinus Pharmaceuticals during the 2nd quarter worth about $232,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.